Related references
Note: Only part of the references are listed.Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease
Kristin D. Kistler et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data
Hannele Yki-Jarvinen
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2010)
Increased Fructose Consumption Is Associated with Fibrosis Severity in Patients with Nonalcoholic Fatty Liver Disease
Manal F. Abdelmalek et al.
HEPATOLOGY (2010)
The Association of Genetic Variability in Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) with Histological Severity of Nonalcoholic Fatty Liver Disease
Yaron Rotman et al.
HEPATOLOGY (2010)
Homozygosity for the Patatin-Like Phospholipase-3/Adiponutrin I148M Polymorphism Influences Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Luca Valenti et al.
HEPATOLOGY (2010)
Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup
Tamaki Yamada et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease
Kitt Falk Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Revisiting the Rosiglitazone Story - Lessons Learned
Clifford J. Rosen
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study
Leon A. Adams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Lifestyle Modification as the Primary Treatment of NASH
Brent A. Neuschwander-Tetri
CLINICS IN LIVER DISEASE (2009)
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis
Eugen Florin Georgescu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-γ activation
T. Yoshida et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet
Haiyan Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats
Koji Fujita et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy
Hui-Min Jin et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Angiotensin II type I receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
Akira Hirose et al.
HEPATOLOGY (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors
T. A. Aksnes et al.
JOURNAL OF HUMAN HYPERTENSION (2006)
Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis
Shiro Yokohama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
The natural history of nonalcoholic fatty liver disease: A population-based cohort study
LA Adams et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Metformin in the treatment of patients with non-alcoholic steatohepatitis
A Uygun et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
S Yokohama et al.
HEPATOLOGY (2004)
Share Paper
